Page 2 - Sun Pharma

Fag-end selling drags Sensex for 6th day, dips 69 pts; RIL slips 1%

Closing Bell: The frontline S&P BSE Sensex fell 69 points to settle at 57,232 levels while the Nifty50 shut shop at 17,063 down 29 points

Stocks to Watch: Mahindra CIE, Dilip Buildcon, SIS, Butterfly Gandhimathi

Stocks like Sun Pharma, Dr.Reddy's and others having exposure to Europe are likel to be in focus as the Russia-Ukraine crisis deepens.

Stocks to Watch: DRL, Mankind, Sun Pharma, Wipro, Kalpataru, TTML, Airlines

Ambuja Cement, Nestle India and Veritas to announce December quarter results today.

Sun Pharma hits six year-high; gains 13% in last eight days on strong Q3

In Q3, the company has witnessed stronger growth than anticipated in the US, Emerging Markets and RoW.

Market wrap: Bulls cheer Budget 2022; Sensex, Nifty end 1.4% higher

Nifty Metal index soars 4%; Tata Steel, SAIL rally; ITC jumps to 7-week high as no tobacco tax relieves investors; Sun Pharma hits new 52-week high post Q3 results; Govt brings cryptos under tax net

Sun Pharma rallies 5%, hits new 52-week high post Q3 results

The management said the company achieved a sustained momentum and good growth across businesses; despite rising costs, achieved higher profitability.

Stocks to Watch: Sun Pharma, UPL, DLF, DB Realty, OMCs, Tata group

Adani Ports, Indian Hotels and Tech Mahindra are some of the prominent companies to announce results today.

Sun Pharma Q3 results: Net profit rises 11% to Rs 2,058.8 crore

In Q3, the revenue from specialty products came in at $183 million, up 21 per cent YoY

Sensex ends 814 pts higher ahead of Budget-day in broad-based rally

Large part of today's rally in the headline indices was led by IT stocks such Tech M, Wipro, Infosys and HCL Tech; financials such as Bajaj twins and SBI, and index heavyweights RIL

Sun Pharma Q3 results: Net profit rises 11% to Rs 2,059 cr

Total revenue from operations rose to Rs 9,863 cr in the third quarter as compared to Rs 8,836.7 cr in the same period of previous fiscal

Sun Pharma-arm Taro logs better-than-expected Q3 Ebitda margin; stock up 4%

In Q3FY22, Taro's EBITDA margins improved 108 bps year-on-year (YoY) to 31.3 per cent mainly due to better gross margins.

Sun Pharma launches dry eye treatment product in Canada

This launch is an important milestone for the drugmaker as it expands its ophthalmics portfolio into Canada, the firm said

Bharti Airtel, L&T, M&M among top trading bets ahead of Budget 2022

Major stocks have broken out on upside, any trigger in Budget 2022 could see sharp up move

Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high

The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.

Sun Pharma expected to shine on domestic prospects, US sales ramp up

Anti-covid drug approval, new facility are the near term triggers for the pharma firm's stock

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Stocks to Watch: Textiles, Amara Raja, Airtel, TCS, ITC, Ajanta Pharma

Textiles shares shall be in limelight as the government has released the operational guidelines for the production-linked incentive (PLI) scheme

Sun Pharma to set up new manufacturing plant in Andhra Pradesh

Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world

Top headlines: Sebi's new measures for IPO market; Covid curbs in Delhi

Business Standard brings you the top headlines on Tuesday

Sun Pharma Advanced Research Co signs licensing pact with Biomodifying

Biomodifying will also receive a percentage of payments received for sublicenses of the licensed IP